Causes of late mortality with dual antiplatelet therapy after coronary stents.

Mauri, Laura; Elmariah, Sammy; Yeh, Robert W; Cutlip, Donald E; Steg, P Gabriel; Windecker, Stephan; Wiviott, Stephen D; Cohen, David J; Massaro, Joseph M; D'Agostino, Ralph B; Braunwald, Eugene; Kereiakes, Dean J (2016). Causes of late mortality with dual antiplatelet therapy after coronary stents. European Heart Journal, 37(4), pp. 378-385. Oxford University Press 10.1093/eurheartj/ehv614

[img] Text
378.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (346kB) | Request a copy

AIMS In the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo. We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study. METHODS AND RESULTS Patients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months. A blinded independent adjudication committee evaluated deaths. Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30). Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33). Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12). Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25). After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16). CONCLUSION Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine. Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding. Caution is warranted when considering extended thienopyridine in patients with advanced cancer. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00977938.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0195-668X

Publisher:

Oxford University Press

Language:

English

Submitter:

Judith Liniger

Date Deposited:

09 Mar 2016 16:05

Last Modified:

09 Mar 2016 16:05

Publisher DOI:

10.1093/eurheartj/ehv614

PubMed ID:

26586780

Uncontrolled Keywords:

Cancer; Dual antiplatelet therapy; Mortality; Thienopyridine

BORIS DOI:

10.7892/boris.75897

URI:

https://boris.unibe.ch/id/eprint/75897

Actions (login required)

Edit item Edit item
Provide Feedback